Literature DB >> 17951552

Patent ductus arteriosus: lack of evidence for common treatments.

Carl L Bose1, Matthew M Laughon.   

Abstract

Patent ductus arteriosus (PDA) is a common diagnosis among extremely premature infants, especially in those with lung disease. Treatments are often used to close the PDA. Despite nearly three decades of research, the question of whether the benefits of treatments to prevent ductal patency or promote closure outweigh the risks of these treatments remains unanswered. The authors rarely use treatments designed to close the PDA. This article reviews three considerations in support of this restrained approach: rates of spontaneous closure of the ductus arteriosus; adverse effect of persistent ductal patency; and benefits and risks of treatments for closure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951552      PMCID: PMC2675405          DOI: 10.1136/adc.2005.092734

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  37 in total

1.  Patent ductus arteriosus; some notes on prognosis and on pulmonary hypertension.

Authors:  M CAMPBELL
Journal:  Br Heart J       Date:  1955-10

2.  Rate of bronchopulmonary dysplasia as a function of neonatal intensive care practices.

Authors:  L J Van Marter; M Pagano; E N Allred; A Leviton; K C Kuban
Journal:  J Pediatr       Date:  1992-06       Impact factor: 4.406

3.  Pulmonary function in preterm infants following treatment with intravenous indomethacin.

Authors:  A N Krauss; N Fatica; B S Lewis; R Cooper; H T Thaler; C Cirrincione; J O'Loughlin; A Levin; M A Engle; P A Auld
Journal:  Am J Dis Child       Date:  1989-01

4.  Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies.

Authors:  R I Clyman
Journal:  J Pediatr       Date:  1996-05       Impact factor: 4.406

5.  Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis.

Authors:  M A Heymann; A M Rudolph; N H Silverman
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

6.  Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease.

Authors:  M A Rojas; A Gonzalez; E Bancalari; N Claure; C Poole; G Silva-Neto
Journal:  J Pediatr       Date:  1995-04       Impact factor: 4.406

7.  Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant.

Authors:  S Shimada; T Kasai; M Konishi; T Fujiwara
Journal:  J Pediatr       Date:  1994-08       Impact factor: 4.406

8.  Pulmonary effects of closure of patent ductus arteriosus in premature infants with severe respiratory distress syndrome.

Authors:  T Farstad; D Bratlid
Journal:  Eur J Pediatr       Date:  1994-12       Impact factor: 3.183

9.  Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus--a double-blind controlled study.

Authors:  T F Yeh; J A Luken; A Thalji; D Raval; I Carr; R S Pildes
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

10.  Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation.

Authors:  J L Stefano; S Abbasi; S A Pearlman; M L Spear; K L Esterly; V K Bhutani
Journal:  Am Rev Respir Dis       Date:  1991-02
View more
  53 in total

1.  Improved closure of patent ductus arteriosus with high doses of ibuprofen.

Authors:  Udo Meißner; Raktima Chakrabarty; Hans-Georg Topf; Wolfgang Rascher; Michael Schroth
Journal:  Pediatr Cardiol       Date:  2012-02-04       Impact factor: 1.655

2.  The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment.

Authors:  Jeff Reese; Matthew M Laughon
Journal:  J Pediatr       Date:  2015-08-24       Impact factor: 4.406

3.  Towards rational management of the patent ductus arteriosus: the need for disease staging.

Authors:  Patrick J McNamara; Arvind Sehgal
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-11       Impact factor: 5.747

Review 4.  Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus?

Authors:  Arvind Sehgal; Patrick J McNamara
Journal:  Eur J Pediatr       Date:  2009-04-22       Impact factor: 3.183

5.  Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.

Authors:  Jonathan L Slaughter; Patricia B Reagan; Thomas B Newman; Mark A Klebanoff
Journal:  JAMA Pediatr       Date:  2017-03-06       Impact factor: 16.193

Review 6.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

7.  Acetaminophen to avoid surgical ligation in extremely low gestational age neonates with persistent hemodynamically significant patent ductus arteriosus.

Authors:  D E Weisz; F F Martins; L E Nield; A El-Khuffash; A Jain; P J McNamara
Journal:  J Perinatol       Date:  2016-04-07       Impact factor: 2.521

8.  Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all?

Authors:  Peter Gal
Journal:  J Pediatr Pharmacol Ther       Date:  2009-01

9.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

10.  Trends in Patent Ductus Arteriosus Diagnosis and Management for Very Low Birth Weight Infants.

Authors:  Samantha Ngo; Jochen Profit; Jeffrey B Gould; Henry C Lee
Journal:  Pediatrics       Date:  2017-04       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.